Cooperative Agreement UG3HL188648

The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan a $2.858 million Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2026.

The University of Michigan will serve as the Clinical Coordinating Center for SPIN VINYL (Systematic Phenotyping and Endotyping in Viral Infections in the Young Lung), a multi-center consortium establishing a harmonized U.S. cohort of 1,500 children aged 0 to 24 months hospitalized with viral lower respiratory tract infections across nine sites. The program will deeply phenotype participants during admission and follow outcomes through at least age 4 to 5 years, integrating clinical trajectories, lung function physiology, imaging, exposome data, objective activity and sleep monitoring, and multi-omics approaches to define severity endotypes and prognostic signatures that explain critical illness and later morbidity. During the UG3 planning phase, the steering committee will approve common protocols, standard operating procedures, training, and centralized biospecimen workflows. Five clinical centers—University of Michigan, Children's Hospital of Philadelphia, Arkansas Children's Hospital, University of Colorado Anschutz, and University of California San Francisco—and four subsites will execute implementation, supported by the Data and Analytics Coordinating Center at the University of Utah.

Place of performance is Ann Arbor, Michigan. The period of performance runs through August 31, 2027. The obligation amount is $2.858 million.